表紙
市場調査レポート

PharmaPoint:髄膜炎菌ワクチン - フランスにおける医薬品の予測と市場分析

PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 275370
出版日 ページ情報 英文 99 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
PharmaPoint:髄膜炎菌ワクチン - フランスにおける医薬品の予測と市場分析 PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
出版日: 2013年09月30日 ページ情報: 英文 99 Pages
概要

当レポートでは、フランスにおける髄膜炎菌ワクチン市場について調査分析し、ワクチンの概要、詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
  • 予後

第4章 疾病管理

  • 髄膜炎予防接種政策
  • フランス

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • Menveo
    • Nimenrix
    • Meningitec
    • Menjugate
    • NeisVac-C
    • Bexsero

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望ワクチン
  • 初期臨床開発中の有望ワクチン

第8章 市場見通し

  • フランス
    • 予測
    • 主なイベント
    • 促進要因・障壁

第9章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1099CFR

GlobalData has released its new Country report, "PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022". Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData does not expect relative patient share to change within the MenC conjugate space because Nuron Biotech's Meningitec, Novartis' Menjugate kit, and Baxter's NeisVac-C all possess similar clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in France and therefore is not expected to change drastically during the forecast period. The French government has expressed disappointment with the low coverage rates of its MenC immunization program and is expected to renew efforts to expand vaccine use (Stahl et al., 2013). In general, the sales potential in France is derived from the immunization recommendations, which largely determine vaccine usage.

Scope

  • Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting France Meningococcal Vaccines market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in France

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis

4. Disease Management

  • 4.1. Meningococcal Immunization Policy
  • 4.2. France
    • 4.2.1. Meningococcal Immunization Recommendations and Policies
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Menveo
    • 5.3.2. Nimenrix
    • 5.3.3. Meningitec
    • 5.3.4. Menjugate
    • 5.3.5. NeisVac-C
    • 5.3.6. Menomune
    • 5.3.7. Bexsero

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Unmet Need: Protection Against Serogroup B Disease
    • 6.2.2. Unmet Need: A Pentavalent (MenABCWY) Vaccine
    • 6.2.3. Unmet Need: More Cost-Effective Vaccines
    • 6.2.4. Unmet Need: Improved Duration of Immunity in Children and Adolescents
    • 6.2.5. Unmet Need: Immunogenic Infant Vaccines
    • 6.2.6. Unmet Need: Improved Vaccination Coverage Rates
    • 6.2.7. Unmet Need: Increased Patient Awareness and Education
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations
    • 6.4.2. Opportunity: Improving Immune Response Duration with Adjuvants
    • 6.4.3. Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Clinical Development
    • 7.2.1. MnB rLP2086
  • 7.3. Promising Vaccines in Early Clinical Development

8. Market Outlook

  • 8.1. France
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccine Approval vs. Routine Schedule Inclusion
    • 9.4.3. Vaccines Included
    • 9.4.4. Key Launch Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Vaccine Assumptions
    • 9.4.7. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Authors
    • 9.6.2. Reviewers
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Meningococcal Disease
  • Table 2: Meningococcal Immunization Recommendation Agencies by Country
  • Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012
  • Table 4: Leading Vaccines for Meningococcal Disease, 2012
  • Table 5: Product Profile - Menveo
  • Table 6: Menveo SWOT Analysis, 2012
  • Table 7: Product Profile - Nimenrix
  • Table 8: Nimenrix SWOT Analysis, 2012
  • Table 9: Product Profile - Meningitec
  • Table 10: Meningitec SWOT Analysis, 2012
  • Table 11: Product Profile - Menjugate
  • Table 12: Menjugate SWOT Analysis, 2012
  • Table 13: Product Profile - NeisVac-C
  • Table 14: NeisVac-C SWOT Analysis, 2012
  • Table 15: Product Profile - Menomune
  • Table 16: Menomune SWOT Analysis, 2012
  • Table 17: Product Profile - Bexsero
  • Table 18: Bexsero SWOT Analysis, 2012
  • Table 19: Overall Unmet Needs - Current Level of Attainment
  • Table 20: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 21: Meningococcal Vaccines - Phase Pipeline, 2012
  • Table 22: Comparison of Vaccines in Development for Meningococcal Disease, 2012
  • Table 23: Product Profile - MnB rLP2086
  • Table 24: MnB rLP2086 SWOT Analysis, 2012
  • Table 25: Sales Forecasts ($m) for Meningococcal Vaccines in France, 2012-2022
  • Table 26: Key Events Impacting Sales for Meningococcal Vaccines in France, 2012-2022
  • Table 27: France Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
  • Table 28: Key Launch Dates
  • Table 29: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Membrane Structure of N. meningitidis
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012-2022
  • Figure 3: Sales for Meningococcal Vaccines in France by Vaccine Class, 2012-2022
Back to Top